Cytokinetics

Quote

anonymous said:
I wouldn’t worry too much about it. You have to wonder about a company that would not submit their REMS info in the hope it wouldn’t be necessary. These things are clearly communicated.

The only plan is to simply go where Camzyos is. No thought at all to a differentiated access strategy at all. If BMS’ network was so good, they would Have more patients being treated.
Click to expand...
You’re absolutely right, I agree with you, 100%!.
 


anonymous said:
I wouldn’t worry too much about it. You have to wonder about a company that would not submit their REMS info in the hope it wouldn’t be necessary. These things are clearly communicated.

The only plan is to simply go where Camzyos is. No thought at all to a differentiated access strategy at all. If BMS’ network was so good, they would Have more patients being treated.
Click to expand...
This! BMS knows their network blows but hides behind their REMS as a reason not to expand access. Funniest thing ever. Like everyone is stupid. I guess this place is going to do the same and wonder why they aren’t successful.
 


anonymous said:
This! BMS knows their network blows but hides behind their REMS as a reason not to expand access. Funniest thing ever. Like everyone is stupid. I guess this place is going to do the same and wonder why they aren’t successful.
Click to expand...
Honestly, it’s like BMS is trying to give this place a gift by allowing Cyto to take business at all the institutions that BMS has been yanking around for years. It appears Cyto is too lazy or stupid to take advantage of this opportunity.
 


Does anyone truly believe this "patients are our North Star stuff" that mix is pushing shoe hard on LinkedIn?

If something is true does it need to be said that much to be believed?

Patients are not, and will never be, the North Star of a publicly traded company. It will always be investors and that which they covet, which is money.
 




anonymous said:
Does anyone truly believe this "patients are our North Star stuff" that mix is pushing shoe hard on LinkedIn?

If something is true does it need to be said that much to be believed?

Patients are not, and will never be, the North Star of a publicly traded company. It will always be investors and that which they covet, which is money.
Click to expand...
If North Star is code for bonus and equity then I believe it.
 


















I came across Cytokinetics and their new drug while browsing LinkedIn and was intrigued by the opportunity, especially with a $180K base salary. However, after speaking with some of my current cardiologist targets, there seems to be skepticism about the l drug’s potential, with several believing it may not perform well in the market.

Good luck to the soldiers go out to die for this.
 





Write your reply...
Top Bottom
Back
Quote